Evidence map›Paper›PMID 39153143›Full record

ArticleInternational journal of clinical pharmacy2024

Characteristics and causes of reported clozapine-related medication errors: analysis of the Ministry of Health database in Saudi Arabia.

Lamaa S AlAmri, Wafa S Alluwaymi, Badr G Alghamdi, Rashed A Alghanim, Afnan S Almordi, Reham F Hettah, Sahar F Almushaikah, Asma M AlShahrani, Nouf T Alshammri, Salma M Aldossari and 3 more

Abstract read
In one paragraph

Article in International journal of clinical pharmacy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lamaa S AlAmriDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, King Khalid International Airport, Airport Road, 11564, Riyadh, Saudi Arabia.
Wafa S AlluwaymiTherapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia.
Badr G AlghamdiTherapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia.
Rashed A AlghanimTherapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia.
Afnan S AlmordiTherapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia.
Reham F HettahTherapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia.
Sahar F AlmushaikahTherapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia.
Asma M AlShahraniTherapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia.
Nouf T AlshammriTherapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia.
Salma M AldossariPharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Leena I AlAwnPharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Nada A AlsalehDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, King Khalid International Airport, Airport Road, 11564, Riyadh, Saudi Arabia.
Ghadah H AlShehriDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, King Khalid International Airport, Airport Road, 11564, Riyadh, Saudi Arabia. ghalshehri@pnu.edu.sa.ORCID http://orcid.org/0000-0001-7807-4470

Funding

Princess Nourah Bint Abdulrahman University PNURSP2024R 352Saudi National Institute of Health for Health Researches SNIH-RO-HRT01-2302-PNU- 36326765
6 · The paper itself

Abstract

backgroundClozapine has shown great efficacy in treating treatment-resistant schizophrenia, but it is associated with a variety of medication- related safety problems. Despite this, there remains a lack of research on medication errors (MEs) associated with its use.

aimTo characterize the nature and contributory factors of clozapine-related MEs reported from government hospitals and primary care centres in Saudi Arabia (SA).

methodA cross-sectional analysis was carried out on MEs related to clozapine use reported to the General Administration of Pharmaceutical Care at the Ministry of Health (MOH) in Saudi Arabia between 2018 and 2022. The data were analysed descriptively to examine the nature and contributory factors of MEs.

resultsA total of 1,165 MEs were reported. The majority of reported errors involved patients aged > 18 years old, with 72.2% (n = 841) being male. The central region was found to report errors more frequently (32.3%, n = 376). Pharmacists were reported to detect errors most frequently (59.6%, n = 695). MEs most often occurred in the prescribing stage (77.8%, n = 906), with "missing prescription information" (30.1%, n = 351) being the most frequent finding. The most frequent contributing factor was the lack of policy (33.1%, n = 351). The majority of errors did not reach the patients (92.3%, n = 1,075), and those that did reach patients rarely resulted in harm (0.3%, n = 2).

conclusionThis study identified areas for improvement which could expedite the development of remedial interventions to reduce the risk of errors.

Indexed as

Antipsychotic AgentsClozapineMedication ErrorsAdolescentAdultAgedCross-Sectional StudiesDatabases, FactualFemaleHumansMaleMiddle AgedPharmacistsSaudi ArabiaSchizophreniaYoung AdultAntipsychotic AgentsClozapineClozapineMedication errorsMinistry of healthSaudi Arabia

Identifiers

PMID39153143
PMCPMC11576782

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.